FDA grants priority review status for AstraZeneca’s bladder cancer drug durvalumab
AstraZeneca’s application (BLA) for durvalumab for BLA in bladder cancer was accepted by the FDA. The PD-L1 human monoclonal antibody…
Pharmaceuticals, Biotechnology and Life Sciences
AstraZeneca’s application (BLA) for durvalumab for BLA in bladder cancer was accepted by the FDA. The PD-L1 human monoclonal antibody…
Eli Lilly and AstraZeneca have announced a worldwide agreement to co-develop MEDI1814, an antibody selective for amyloid-beta 42 (Aβ42), which…
AstraZeneca has announced that Jean-Philippe Courtois, a Non-Executive Director, will step down from the Board of AstraZeneca…
AstraZeneca’s high hopes for cancer immunotherapy were dented on Thursday as the recruitment
AstraZeneca’s Lynparza tablets against BRCA-mutated ovarian cancer have shown…
Biocartis Group NV, a Belgian innovative molecular diagnostics company has published a comparative study organised by AstraZeneca where 12 different KRAS mutation detecting technologies, including Next-Generation Sequencing (NGS) and quantitative Polymerase Chain Reaction (PCR), were compared for the detection of KRAS mutations in lung cancer, using blinded samples.
AstraZeneca’s heart drug Brilinta has failed to help patients with serious circulatory problems in their legs, dealing a blow to a medicine that the company has tipped as a potential $3.5 billion-a-year seller by 2023.
AstraZeneca has entered into an agreement with LEO Pharma A/S (LEO Pharma), a specialist in dermatology care, for the global licence to tralokinumab in skin diseases. As explained by AstraZeneca, Tralokinumab is a potential new medicine (an anti-IL-13 monoclonal antibody) that has completed a Phase IIb trial for the treatment of patients with atopic dermatitis, an inflammatory skin disease resulting in itchy, red, swollen and cracked skin.
drugmaker Sanofi has poached one of AstraZeneca’s top scientists to be its new research head in another high-profile departure for the British drugmaker.
AstraZeneca on Wednesday announced the results of the SOCRATES trial, assessing the efficacy of Brilinta/Brilique (ticagrelor) 90 mg tablets twice daily, when compared to aspirin 100mg once daily in patients with acute ischaemic stroke or transient ischaemic attack (TIA)